FY2026 Earnings Forecast for Travere Therapeutics, Inc. Issued By Wedbush (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Investment analysts at Wedbush upped their FY2026 earnings per share (EPS) estimates for Travere Therapeutics in a research note issued to investors on Wednesday, October 9th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of $2.81 for the year, up from their prior estimate of $2.28. Wedbush currently has a “Outperform” rating and a $25.00 price objective on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.95) per share. Wedbush also issued estimates for Travere Therapeutics’ FY2027 earnings at $3.83 EPS and FY2028 earnings at $3.92 EPS.

A number of other equities research analysts have also recently weighed in on TVTX. HC Wainwright dropped their price target on Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a report on Friday, September 27th. Bank of America raised their target price on Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup cut their price target on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a report on Friday, September 27th. Barclays increased their price objective on shares of Travere Therapeutics from $14.00 to $18.00 and gave the stock an “overweight” rating in a report on Tuesday, October 1st. Finally, Guggenheim boosted their target price on shares of Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.75.

Travere Therapeutics Stock Performance

NASDAQ:TVTX opened at $17.11 on Friday. The company has a current ratio of 3.04, a quick ratio of 2.99 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $18.60. The firm has a 50 day moving average of $11.63 and a 200-day moving average of $8.90.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). The firm had revenue of $54.12 million during the quarter, compared to analyst estimates of $49.50 million. Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%.

Insider Buying and Selling

In other Travere Therapeutics news, SVP William E. Rote sold 4,387 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $50,538.24. Following the transaction, the senior vice president now owns 84,455 shares of the company’s stock, valued at approximately $972,921.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Travere Therapeutics news, SVP William E. Rote sold 4,387 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $50,538.24. Following the completion of the sale, the senior vice president now owns 84,455 shares of the company’s stock, valued at approximately $972,921.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey A. Meckler sold 40,000 shares of the company’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $14.06, for a total transaction of $562,400.00. Following the completion of the sale, the director now owns 81,000 shares of the company’s stock, valued at approximately $1,138,860. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 110,707 shares of company stock valued at $1,504,312 over the last ninety days. Insiders own 3.75% of the company’s stock.

Institutional Investors Weigh In On Travere Therapeutics

A number of hedge funds have recently modified their holdings of TVTX. EntryPoint Capital LLC bought a new stake in Travere Therapeutics during the 1st quarter worth approximately $32,000. CWM LLC boosted its holdings in shares of Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after buying an additional 3,065 shares during the period. Diversified Trust Co acquired a new position in shares of Travere Therapeutics in the third quarter valued at approximately $161,000. DRW Securities LLC bought a new stake in shares of Travere Therapeutics during the second quarter worth $95,000. Finally, Forefront Analytics LLC raised its holdings in shares of Travere Therapeutics by 10.2% during the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after acquiring an additional 1,237 shares during the period.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.